0074sek
6,3 %
Date:2024-07-24Time:17:29:00Latest report:Q1-2024List:First NorthTicker:CMH
Market Cap:36 msekEnterprise Value:16 msekNet Sales:1,11 msekEarnings:-28,1 msekEmployees:0ISIN:SE0009495559

Ratios

10-year key figure history for Chordate Medical turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Chordate Medical with index and moving average MA50 and MA200.

Stockprice:0,074
MA50:0,06
MA200:0,13
Price/MA200:-41,1 %
RSI (14):66,2
Price/MA50:25,8 %

Description

Chordate Medical Holding AB is a medical technology company that has developed patented and CE-marked a new nerve-modulating treatment technology for chronic nasal congestion and chronic migraine. The company sells its products in Selected European markets, Israel, and Saudi Arabia. The company’s product range is based on the CE-marked treatment units Chordate System S100 and S120 for rhinitis and S220 for migraine, registered for the indications of preventive treatment of chronic migraine and chronic rhinitis and use on patients. The company sells its product system, including treatments, through distributors to clinics and hospitals in its primary markets.

Medical Equipment